Coherus BioSciences, Inc.
Coherus BioSciences, Inc., a leading biotechnology firm headquartered in the United States, focuses on the development and commercialisation of innovative biologic therapies. Founded in 2010, the company has made significant strides in the biosimilars market, particularly in oncology and autoimmune diseases. With a robust portfolio that includes products like Udenyca, Coherus stands out for its commitment to providing high-quality, cost-effective alternatives to expensive biologic treatments. The company operates primarily in North America, with a growing presence in international markets. Recognised for its scientific expertise and strategic partnerships, Coherus BioSciences has established a strong market position, contributing to the accessibility of essential therapies for patients worldwide.
DitchCarbon Score
How does Coherus BioSciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Coherus BioSciences, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Coherus BioSciences, Inc.'s reported carbon emissions
Coherus BioSciences, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Coherus BioSciences has not inherited any emissions data from a parent or related organization, and there are no climate initiatives or commitments reported through recognised frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the biopharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific data or commitments from Coherus BioSciences, it is unclear how they align with these industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Coherus BioSciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
